When you think of arthritis, achy, warm, swollen joints probably come to mind. These are indeed some of the most common symptoms of arthritis. But did you know there are actually over 100 different ...
NEW YORK CITY — Urate, the culprit of gout, affects the vasculature in multiple ways that can raise cardiovascular risk (CV) in an individual with gout, and following guidelines for gout treatment, ...
GlobalData on MSN
Sobi buys Arthrosi to expand gout treatment pipeline
Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.
The study revealed how a second drug taken orally more than doubled the effectiveness of Pegloticase, an intravenous gout treatment used to dissolve crystalized uric acid in the joints when oral ...
PHILADELPHIA — Patients with gout who underwent an intensive treat-to-target regimen of monthly up-titration of urate-lowering therapy (ULT) to reach a target serum urate level were significantly more ...
“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has the potential to become the therapy of choice for patients who have ...
WASHINGTON — Different stages of gout treatment may call for different serum urate targets, with certain levels being better for dissolving or preventing monosodium urate crystals, according to data ...
Per the terms of the agreement, Sobi is expected to pay upwards of $950 million upfront in cash to acquire Arthrosi.The deal also includes up to $550 million in cash in clinical, regulatory, and sales ...
The study revealed how a second drug taken orally more than doubled the effectiveness of Pegloticase, an intravenous gout treatment used to dissolve crystalized uric acid in the joints when oral ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...
Sobi agrees to buy Arthrosi Therapeutics for up to $1.5 billion, adding the Phase 3 gout asset pozdeutinurad to expand its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback